These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9664948)

  • 21. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.
    Lancet; 1994 Aug; 344(8920):423-8. PubMed ID: 7520105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
    Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
    Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.
    Margreiter R;
    Lancet; 2002 Mar; 359(9308):741-6. PubMed ID: 11888584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
    Laskow DA; Vincenti F; Neylan JF; Mendez R; Matas AJ
    Transplantation; 1996 Oct; 62(7):900-5. PubMed ID: 8878381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group.
    Devlin J; Williams R
    Transplantation; 1996 Nov; 62(9):1251-5. PubMed ID: 8932266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group.
    Klein A
    Liver Transpl Surg; 1999 Nov; 5(6):502-8. PubMed ID: 10545538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.
    Saudek F; Malaise J; Boucek P; Adamec M;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii3-10, ii62. PubMed ID: 15814547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
    McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
    J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine versus tacrolimus maintenance therapy in renal transplant.
    Alghamdi S; Nabi Z; Skolnik E; Alkorbi L; Albaqumi M
    Exp Clin Transplant; 2011 Jun; 9(3):170-4. PubMed ID: 21649564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.
    Trompeter R; Filler G; Webb NJ; Watson AR; Milford DV; Tyden G; Grenda R; Janda J; Hughes D; Ehrich JH; Klare B; Zacchello G; Bjorn Brekke I; McGraw M; Perner F; Ghio L; Balzar E; Friman S; Gusmano R; Stolpe J
    Pediatr Nephrol; 2002 Mar; 17(3):141-9. PubMed ID: 11956848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
    Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
    J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.